Synergy was observed with the addition of anti-PD-1 and anti-CTLA-4 treatments relative to monotherapy, with further reductions in tumor growth and a reduction of the suppressive character of myeloid cells in the TME. The gene discussed is PDCD1; the disease is neoplasm.